Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer (IMMU-132-06)
- Details
ClinicalTrials.gov ID:
NCT03547973
Diagnosis Type:
NA
USOR Number:
- Address
,
P: